Peripheral adenosine infusion versus central access infusion during measurement of FFR

Original title: FFR in the Transradial Era: Will Hand Vein Adenosine Infusion Suffice?A Comparative Study of the Extent, Rapidity, and Stability of Hyperemia From Hand and Femoral Venous Routes of Adenosine Administration. Reference: Peter Scott et al. J Am Coll Cardiol Intv. 2015, online before print.

 

The aim of this study was to compare the administration of adenosine by a path in the back of the hand versus the same drug administration using a central venous access and observe differences to reach peak hyperemia during measurement of fractional flow reserve (FFR). Adenosine is commonly used to achieve maximum hyperemia during the measurement of FFR and the gold standard is administered by a central venous access. With the proliferation of radial access is desirable to have an alternative route around, however, it is unclear whether it is possible to achieve maximum hyperemia using a peripheral access.

Patients scheduled for FFR measurement were selected and administered adenosine sequentially through a 20G cannula into the back of the hand and after a washout of the drug, adenosine was re-administered through an inserter 5 or 6 Fr in the femoral vein. Adenosine was given at 140 ug / kg / min for each access. The interpretation of the data was blind regarding the administration via. Measurements were performed in 84 vessels of 61 patients with a mean value of FFR of 0.85 (0.986 correlation between both accesses). Hyperemia peak time was different, requiring an average of 22 seconds more for peripheral access (63 seconds versus 43 seconds; p <0.0001).

Conclusion

Adenosine infusion during FFR measurement by peripheral access is similar to the administration thereof by central access. This is important from a practical point of view for performing radial access procedures.

Editorial comment

In the FAME study, according to protocol, 140 ug / kg / min of adenosine by femoral venous access were administered and although in daily practice this same dose was often administered peripherally, there was so far, no evidence that it was equivalent. This is an interesting technical detail which increases the comfort of patients receiving radial access in the procedure.

SOLACI

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....